Content
We reassessed potentially prognostic blood biomarkers in multiple sclerosis. This supplementary material provides results from the further validation using the Affymetrix microarray data from Gurevich et al. (BMC Med Genomics, 2009) . The data provide PBMC transcript levels of 32 CIS and 62 MS patients. We grouped patients with "poor" and "good" disease course depending on whether they had at least one documented relapse within two years after the blood sampling.
Additionally, for the 15 genes that were differentially expressed in our data between patient groups with different clinical response status, we compared the PBMC expression levels to those of patients with chronic fatigue syndrome, rheumatoid arthritis and healthy individuals. Table S1 : Mean gene expression levels in different diseases and healthy subjects.
In our data, 15 of the 112 evaluated biomarker candidate genes were significantly higher or lower expressed in patients with worse disease progression than in patients having no relapse and no strongly increased EDSS during follow-up (see main text). For those genes, we compared the PBMC transcript levels of our 49 MS patients with those of patients with chronic fatigue syndrome (CFS), patients with rheumatoid arthritis (RA) and healthy individuals (HS). For this purpose, we used another microarray data set generated in our group (Koczan et al., Arthritis Res Ther, 2008) and an external data set (Gow et al., BMC Med Genomics, 2009) . Each data set consists of Affymetrix HG-U133 A chips that were preprocessed uniformly to provide the expression levels of 12175 genes (see main text). The accessions of the GEO and ArrayExpress databases are given in the table as well as minimum, maximum, mean and median of the measured signal intensities per data set, and mean ± standard deviation for each gene. Red, yellow and white cell colors represent high, medium and low mRNA amounts, respectively.
The table indicates higher levels of IL17RC, IL1RN and FPR2, and lower levels of IL7 in MS and RA samples compared to CFS and HS samples. However, since the data for CFS and HS were obtained by another lab, systematic differences between the data sets are likely and thus the results should be interpreted with caution. (n=43) and "poor" (n=51) course of disease. For an arbitrary signal cut-off, the ROC curve displays the false positive rate (1 -specificity) against the recall (sensitivity). The better the predictions, the closer the resulting curve will be to the upper-left corner. We used the ROC curves to determine appropriate signal cut-off values defining "low" and "high" expression for both genes. The area under the curve is 0.719 in case of GPR3, and 0.721 in case of IL17RC. Figure S3 : Kaplan-Meier survival curves for low and high expression of GPR3 and IL17RC. The curves visualize the proportion of relapse-free patients after the blood sampling. Of the 94 patients included in the study by Gurevich et al., 21 had "high" and 73 had "low" GPR3 levels. Analogously, 41 patients had "high" and 53 had "low" IL17RC levels. The differences between the survival curves of patients with low and high expression were significant according to the logrank test for GPR3 (pvalue=0.0006) as well as for IL17RC (p-value=0.0009). Hazard ratio and 95% confidence interval retrieved from a Cox proportional hazards model were 3.4 (1.6-7.2) for GPR3, and 2.35 (1.4-4.0) for IL17RC. According to this, low expression of GPR3 and IL17RC is associated with a shorter time to the next relapse.
